NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis $1.16 +0.04 (+3.57%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TherapeuticsMD Stock (NASDAQ:TXMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TherapeuticsMD alerts:Sign Up Key Stats Today's Range$1.11▼$1.2150-Day Range$1.08▼$1.5252-Week Range$0.70▼$2.44Volume70,415 shsAverage Volume159,983 shsMarket Capitalization$13.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More… TherapeuticsMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreTXMD MarketRank™: TherapeuticsMD scored higher than 30% of companies evaluated by MarketBeat, and ranked 821st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for TherapeuticsMD. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TherapeuticsMD's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.37% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently decreased by 50.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.37% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently decreased by 50.42%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentTherapeuticsMD has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TherapeuticsMD this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for TXMD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,803.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of TherapeuticsMD is held by insiders.Percentage Held by InstitutionsOnly 30.74% of the stock of TherapeuticsMD is held by institutions.Read more about TherapeuticsMD's insider trading history. Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address TXMD Stock News HeadlinesMarlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street JournalJune 29 at 4:37 PM | wsj.comMayne Pharma Files Legal Complaint Against TherapeuticsMDJune 1, 2025 | tipranks.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 1 at 2:00 AM | Crypto 101 Media (Ad)TherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12, 2025 | marketwatch.comTherapeuticsMD Inc. stock outperforms competitors despite losses on the dayApril 8, 2025 | marketwatch.comTherapeuticsMD Announces Full Year 2024 Financial ResultsMarch 27, 2025 | businesswire.comTherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo FinanceMarch 26, 2025 | finance.yahoo.comSee More Headlines TXMD Stock Analysis - Frequently Asked Questions How have TXMD shares performed this year? TherapeuticsMD's stock was trading at $0.86 on January 1st, 2025. Since then, TXMD stock has increased by 34.9% and is now trading at $1.16. View the best growth stocks for 2025 here. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.06) EPS for the quarter. The business earned $0.39 million during the quarter. TherapeuticsMD had a negative net margin of 114.07% and a negative trailing twelve-month return on equity of 7.86%. When did TherapeuticsMD's stock split? Shares of TherapeuticsMD reverse split on Monday, May 9th 2022.The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Marinus Pharmaceuticals (MRNS), AU Optronics (AUOTY) and The RMR Group (RMR). Company Calendar Last Earnings5/13/2025Today6/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees420Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.18 million Net Margins-114.07% Pretax Margin-119.61% Return on Equity-7.86% Return on Assets-5.46% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual Sales$1.84 million Price / Sales7.29 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.49Miscellaneous Outstanding Shares11,574,000Free Float11,308,000Market Cap$13.43 million OptionableOptionable Beta0.65 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TXMD) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.